Armistice Capital LLC recently announced the acquisition of new stake in Voyager Therapeutics Inc (NASDAQ:VYGR). The institutional investor has increased its shareholding in the Healthcare company by 15.29% to 4.18 million shares with purchase of 0.55 million shares. This fresh investment now brings its stake to 9.50% valued currently at $35.26 million. In addition, The Vanguard Group, Inc. raised its holdings by 4989.0 to 2.42 million shares. And Dimensional Fund Advisors LP has lifted its position by 133.64% or 0.45 million shares – to 0.78 million shares.
With over 0.46 million Voyager Therapeutics Inc (VYGR) shares trading Friday and a closing price of $7.86 on the day, the dollar volume was approximately $3.62 million. The shares have shown a negative half year performance of -17.35% and its price on 01/12/24 lost nearly -1.75%. Currently, there are 38.61M common shares owned by the public and among those 36.52M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for VYGR have a consensus price objective of $15.33. The analysts have set the share’s price value over the next 12 months at a high of $18.00 and a low of $10.00. The average price target is 48.73% above its recent price level and an upside to the estimated low will see the stock gain 21.4% over that period. But an upside of 56.33% will see the stock hit the forecast high price target while median target price for the stock is $16.00.
Insiders at the company have transacted a total of 37 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 4,698,588 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 2,325,717 shares.
The top 3 mutual fund holders in Voyager Therapeutics Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and T Rowe Price Health Sciences Fund. Vanguard Total Stock Market ETF owns 1.34 million shares of the company’s stock, all valued at over $11.35 million. iShares Russell 2000 ETF sold 2214.0 shares to see its total holdings shrink to 0.84 million shares valued at over $7.08 million and representing 1.91% of the shares outstanding. T Rowe Price Health Sciences Fund sold 19905.0 shares to bring its total holdings to over 0.7 million shares at a value of $5.92 million. T Rowe Price Health Sciences Fund now owns shares totaling to 1.59% of the shares outstanding.
Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) opened at $8.08, up $0.08 from a prior closing price of $8.00. The company’s stock has a 5-day price change of -11.19% and 7.97% over the past three months. VYGR shares are trading -6.87% year to date (YTD), with the 12-month market performance down to -12.18% lower. It has a 12-month low price of $6.06 and touched a high of $14.34 over the same period. VYGR has an average intraday trading volume of 596.95K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.06%, 3.09%, and -11.56% respectively.
Institutional ownership of Voyager Therapeutics Inc (NASDAQ: VYGR) shares accounts for 57.57% of the company’s 38.61M shares outstanding. Mutual fund holders own 29.16%, while other institutional holders and individual stakeholders account for 38.02% and 22.39% respectively.
It has a market capitalization of $362.74M and a beta (3y monthly) value of 0.99. The stock’s trailing 12-month PE ratio is 6.40, while the earnings-per-share (ttm) stands at $1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.63% over the week and 7.34% over the month.
Analysts forecast that Voyager Therapeutics Inc (VYGR) will achieve an EPS of -$0.29 for the current quarter, -$0.25 for the next quarter and -$1.84 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.62 while analysts give the company a high EPS estimate of $1.33. Comparatively, EPS for the current quarter was -$0.61 a year ago. Earnings per share for the fiscal year are expected to increase by 218.79%, and -227.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Voyager Therapeutics Inc (VYGR) as a “Strong Buy” at a consensus score of 1.43. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 1 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the VYGR, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on January 02, 2024, with the firm’s price target at $14.
